pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
RHAPSIDO · news · pharmadog
← back to RHAPSIDO
News mentioning RHAPSIDO
10
stories
5d
FDA starts review of Roche’s multiple sclerosis pill
biopharma dive
20d
Novartis ends ALS program after phase 2 flop, adding to R&D woes
fiercebiotech
25d
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
biospace
26d
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
fiercebiotech
28d
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
fiercebiotech
Sep 2, 26
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
biospace
Sep 1, 26
Novartis says MS pill succeeds in two large studies
biopharma dive
Sep 1, 26
Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest
endpoints
Jul 29, 26
Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido
fiercebiotech
Jul 21, 26
Novartis climbs on upbeat drug sales as key readouts loom
biopharma dive
